CIBC Asset Management Inc Acquires 14,000 Shares of Astrazeneca PLC (AZN)
CIBC Asset Management Inc increased its holdings in shares of Astrazeneca PLC (NYSE:AZN) by 11.7% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 133,340 shares of the company’s stock after acquiring an additional 14,000 shares during the period. CIBC Asset Management Inc’s holdings in Astrazeneca PLC were worth $4,518,000 at the end of the most recent reporting period.
Several other institutional investors have also modified their holdings of AZN. Voya Investment Management LLC boosted its position in Astrazeneca PLC by 38.2% in the second quarter. Voya Investment Management LLC now owns 2,395,465 shares of the company’s stock valued at $81,661,000 after buying an additional 662,481 shares in the last quarter. Russell Investments Group Ltd. boosted its position in Astrazeneca PLC by 746.0% in the second quarter. Russell Investments Group Ltd. now owns 620,901 shares of the company’s stock valued at $21,167,000 after buying an additional 547,512 shares in the last quarter. Fisher Asset Management LLC boosted its position in Astrazeneca PLC by 4.7% in the third quarter. Fisher Asset Management LLC now owns 11,601,573 shares of the company’s stock valued at $393,061,000 after buying an additional 519,717 shares in the last quarter. State Street Corp acquired a new position in Astrazeneca PLC in the second quarter valued at about $14,536,000. Finally, Suffolk Capital Management LLC acquired a new position in Astrazeneca PLC in the second quarter valued at about $12,591,000. Institutional investors and hedge funds own 14.16% of the company’s stock.
A number of equities analysts have commented on the stock. BMO Capital Markets set a $38.00 price target on shares of Astrazeneca PLC and gave the company a “buy” rating in a research report on Wednesday. Piper Jaffray Companies restated a “buy” rating on shares of Astrazeneca PLC in a research report on Wednesday, August 9th. BidaskClub lowered shares of Astrazeneca PLC from a “sell” rating to a “strong sell” rating in a research report on Friday, August 4th. Cowen and Company restated a “hold” rating and issued a $37.00 price target on shares of Astrazeneca PLC in a research report on Tuesday, October 17th. Finally, Credit Suisse Group upgraded shares of Astrazeneca PLC from a “neutral” rating to an “outperform” rating in a research report on Monday, October 16th. Four research analysts have rated the stock with a sell rating, eight have given a hold rating and twelve have assigned a buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $34.20.
TRADEMARK VIOLATION NOTICE: This article was posted by Daily Political and is the property of of Daily Political. If you are reading this article on another site, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The original version of this article can be viewed at https://www.dailypolitical.com/2017/11/16/cibc-asset-management-inc-acquires-14000-shares-of-astrazeneca-plc-azn.html.
Shares of Astrazeneca PLC (AZN) opened at $33.39 on Thursday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 0.72 and a current ratio of 0.94. The firm has a market cap of $84,185.54, a P/E ratio of 7.94, a P/E/G ratio of 3.14 and a beta of 0.75. Astrazeneca PLC has a 12 month low of $25.55 and a 12 month high of $35.60.
Astrazeneca PLC (NYSE:AZN) last posted its quarterly earnings results on Thursday, November 9th. The company reported $1.12 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.57 by $0.55. Astrazeneca PLC had a net margin of 15.90% and a return on equity of 34.02%. The business had revenue of $6.23 billion during the quarter, compared to the consensus estimate of $6 billion. During the same period in the previous year, the firm posted $1.32 earnings per share. Astrazeneca PLC’s revenue for the quarter was up 9.4% compared to the same quarter last year. analysts predict that Astrazeneca PLC will post 1.93 EPS for the current year.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Astrazeneca PLC (NYSE:AZN).
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.